Does cortical brain morphology act as a mediator between childhood trauma and transition to psychosis in young individuals at ultra-high risk?

Marta Rapado-Castro; Sarah Whittle; Christos Pantelis; Andrew Thompson; Barnaby Nelson; Eleni P Ganella; Ashleigh Lin; Renate LEP Reniers; Patrick D McGorry; Alison R Yung; Stephen J Wood; Cali F Bartholomeusz

Journal article

Does cortical brain morphology act as a mediator between childhood trauma and transition to psychosis in young individuals at ultra-high risk?

Marta Rapado-Castro, Sarah Whittle, Christos Pantelis, Andrew Thompson, Barnaby Nelson, Eleni P Ganella, Ashleigh Lin, Renate LEP Reniers, Patrick D McGorry, Alison R Yung, Stephen J Wood, Cali F Bartholomeusz

SCHIZOPHRENIA RESEARCH | ELSEVIER | Published : 2020

DOI: 10.1016/j.schres.2020.09.017

Download PDF

Abstract

BACKGROUND: Childhood trauma, particularly sexual abuse, has been associated with transition to psychosis in individuals at "ultra-high risk" (UHR). This study investigated whether the effects of various forms of childhood trauma on transition to psychosis are mediated by cortical thickness and surface area abnormalities. METHODS: This prospective study used data from 62 UHR individuals from a previous (PACE 400) cohort study. At follow-up, 24 individuals had transitioned to psychosis (UHR-T) and 38 individuals had not transitioned (UHR-NT). Student-t/Mann-Whitney-U tests were performed to assess morphological differences in childhood trauma (low/high) and transition. Mediation analyses were..

View full abstract

University of Melbourne Researchers

Sarah Whittle Author Psychiatry

Marta Rapado-Castro Author Psychiatry

Christos Pantelis Author Psychiatry

Stephen Wood Author Centre for Youth Mental Health

Cali Bartholomeusz Author Centre for Youth Mental Health

Related Projects (4)

EMERGING MENTAL DISORDERS IN YOUNG PEOPLE: USING CLINICAL STAGING FOR PREDICTION, PREVENTION AND EARLY INTERVENTION

Mental disorders are a major cause of disability in Australia, especially for young people. We have developed a clinical staging model cover..

RESEARCH FELLOWSHIP - PROF CHRISTOS PANTELIS

I have established and head the Melbourne Neuropsychiatry Centre within the University of Melbourne. My university position is a research ch..

NEURODEVELOPMENTAL RISK FACTORS FOR DEPRESSION FROM CHILDHOOD TO EARLY ADULTHOOD

To understand who is at risk for depression, we need to understand how both the environment and biological factors promote risk at specific ..

CAN WE PREDICT PSYCHOSIS AND CAN IT BE PREVENTED?

It remains unclear what the causes of schizophrenia and other psychotic disorders are and what the most effective interventions are for prev..

Grants

Awarded by Ramon y Cajal Research Fellowship

Awarded by Institute of Health Carlos III

Awarded by Brain & Behavior Research Foundation

Awarded by Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III

Awarded by CIBERSAM, Madrid Regional Government

Awarded by NHMRC

Awarded by NHMRC Australian-based Senior Principal Research Fellowship

Funding Acknowledgements

MR-C was supported by a Ramon y Cajal Research Fellowship (RYC-2017-23144), Spanish Ministry of Science, Innovation and Universities, a Sara Borrell Health Research Fellowship (CD10/00158) from the Institute of Health Carlos III, Spanish Ministry of Economy and Competitiveness, an Alicia Koplowitz Research Grant and Short-Term Visiting Fellowship from the Alicia Koplowitz Foundation, a Fellowship Award from the Health Research Institute, Hospital Gregorio Maranon (Madrid, Spain), and a NARSAD independent investigator grant (24628) from the Brain & Behavior Research Foundation. MR-C was partially supported by the Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III (PI15/00723, PI18/00753), co-financed by ERDF Funds from the European Commission, "A way of making Europe", CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds and European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint; Fundacion Familia Alonso, Fundacion Alicia Koplowitz and Fundacion Mutua Madrilena. BN was supported by an NHMRC Senior Research Fellowship (1137687). AL is supported by a NHMRC Career Development Fellowship (1148793). SW was supported by a NHMRC Career Development Fellowship (1125504). CP has received a NHMRC Australian-based Senior Principal Research Fellowship (628386), NARSAD Distinguished Investigator Award, and NHMRC Program Grant (566529); he has received grant support from Janssen-Cilag, Eli Lilly, Hospira (Mayne), Astra Zeneca and has provided consultancy to Janssen-Cilag, Eli Lilly, Hospira (Mayne), Astra Zeneca, Pfizer, Schering Plough, Lundbeck. He has undertaken investigator initiated studies supported by Eli Lilly, Hospira, Janssen Cilag and Astra Zeneca.